XXXX Related to Commonly Used New Antidepressants.

@entity1 @entity903 @entity837 @entity4480 @entity750 @entity936 @entity906 @entity1063
UNASSIGNED: Antidepressants may have an impact on the course of eye dryness. The aim of this study was to investigate the effects of commonly used new antidepressants on eye wetting. Fifty-four @entity1 using new antidepressants and 57 controls were recruited. The Beck Depression Scale and Beck Anxiety Scale questionnaires were completed by the @entity1 , and drug use time and dosages were recorded. The Schirmer test was performed without prior instillation of topical anesthesia to the ocular surface, and the wetting result was recorded for each eye. @entity837 , @entity4480 , and @entity906 were used by 27, 13, and 14 @entity1 , respectively. The Schirmer test results in the @entity1 were significantly lower than in the controls (P < 0.001). The @entity1 using selective @entity750 reuptake inhibitors (SSRIs) displayed lower wetting measurements ( <=5 mm) compared with those using @entity750 - @entity1063 reuptake inhibitors, which was independent of the duration of antidepressant usage (P < 0.05). Although SSRIs do not have anticholinergic adverse effects except @entity903 , we found that both SSRIs and @entity750 - @entity1063 reuptake inhibitors increased the risk for eye dryness. The lower Schirmer test results of the SSRIs may be associated with a mechanism other than the anticholinergic system. An awareness of the drugs that contribute to @entity936 will allow ophthalmologists, optometrists, and other physicians to better manage @entity1 who have this problem.
